These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 32826327)

  • 1. Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.
    Axelrod ML; Nixon MJ; Gonzalez-Ericsson PI; Bergman RE; Pilkinton MA; McDonnell WJ; Sanchez V; Opalenik SR; Loi S; Zhou J; Mackay S; Rexer BN; Abramson VG; Jansen VM; Mallal S; Donaldson J; Tolaney SM; Krop IE; Garrido-Castro AC; Marotti JD; Shee K; Miller TW; Sanders ME; Mayer IA; Salgado R; Balko JM
    Clin Cancer Res; 2020 Nov; 26(21):5668-5681. PubMed ID: 32826327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
    Loibl S; Untch M; Burchardi N; Huober J; Sinn BV; Blohmer JU; Grischke EM; Furlanetto J; Tesch H; Hanusch C; Engels K; Rezai M; Jackisch C; Schmitt WD; von Minckwitz G; Thomalla J; Kümmel S; Rautenberg B; Fasching PA; Weber K; Rhiem K; Denkert C; Schneeweiss A
    Ann Oncol; 2019 Aug; 30(8):1279-1288. PubMed ID: 31095287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
    Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S
    Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
    Lee J; Kim DM; Lee A
    Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
    Adams S; Diamond JR; Hamilton E; Pohlmann PR; Tolaney SM; Chang CW; Zhang W; Iizuka K; Foster PG; Molinero L; Funke R; Powderly J
    JAMA Oncol; 2019 Mar; 5(3):334-342. PubMed ID: 30347025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer.
    Ahmed FS; Gaule P; McGuire J; Patel K; Blenman K; Pusztai L; Rimm DL
    Clin Cancer Res; 2020 Oct; 26(20):5456-5461. PubMed ID: 32709714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
    Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
    Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
    Loi S; Dushyanthen S; Beavis PA; Salgado R; Denkert C; Savas P; Combs S; Rimm DL; Giltnane JM; Estrada MV; Sánchez V; Sanders ME; Cook RS; Pilkinton MA; Mallal SA; Wang K; Miller VA; Stephens PJ; Yelensky R; Doimi FD; Gómez H; Ryzhov SV; Darcy PK; Arteaga CL; Balko JM
    Clin Cancer Res; 2016 Mar; 22(6):1499-509. PubMed ID: 26515496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
    Li CJ; Lin LT; Hou MF; Chu PY
    Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
    Graeser M; Feuerhake F; Gluz O; Volk V; Hauptmann M; Jozwiak K; Christgen M; Kuemmel S; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kolberg-Liedtke C; Kates R; Wuerstlein R; Nitz U; Kreipe HH; Harbeck N
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
    Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.
    Gazinska P; Milton C; Iacovacci J; Ward J; Buus R; Alaguthurai T; Graham R; Akarca A; Lips E; Naidoo K; Wesseling J; Marafioti T; Cheang M; Gillett C; Wu Y; Khan A; Melcher A; Salgado R; Dowsett M; Tutt A; Roxanis I; Haider S; Irshad S
    Clin Cancer Res; 2022 Oct; 28(20):4494-4508. PubMed ID: 36161312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8
    Fukuoka E; Yamashita K; Tanaka T; Sawada R; Sugita Y; Arimoto A; Fujita M; Takiguchi G; Matsuda T; Oshikiri T; Nakamura T; Suzuki S; Kakeji Y
    Anticancer Res; 2019 Aug; 39(8):4539-4548. PubMed ID: 31366557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Abdelrahman AE; Rashed HE; MostafaToam ; Omar A; Abdelhamid MI; Matar I
    Ann Diagn Pathol; 2021 Apr; 51():151676. PubMed ID: 33360026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
    Wesolowski R; Stiff A; Quiroga D; McQuinn C; Li Z; Nitta H; Savardekar H; Benner B; Ramaswamy B; Lustberg M; Layman RM; Macrae E; Kassem M; Williams N; Sardesai S; VanDeusen J; Stover D; Cherian M; Mace TA; Yu L; Duggan M; Carson WE
    BMC Cancer; 2020 May; 20(1):445. PubMed ID: 32429929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis.
    Li X; Tan Q; Li H; Yang X
    J Surg Oncol; 2021 Jan; 123(1):89-95. PubMed ID: 33047336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.